Status:
COMPLETED
Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Kyung Hee University Hospital at Gangdong
Conditions:
Neurogenic Orthostatic Hypotension
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
This was a randomized, open-label clinical trial. We will enroll patients with symptomatic neurogenic OH and randomize them to 1 of 2 treatments: (1) midodrine only, (2) atomoxetine only. We will foll...
Detailed Description
Visit 1. 1. Enroll, baseline evaluation of the patients 2. Questionnaire * Evaluate orthostatic hypotension symptom: Orthostatic Hypotension Questionnaire (OHQ) * Quality of life: Korean versi...
Eligibility Criteria
Inclusion
- Age \>=19 patients who complained of dizziness
- Orthostatic hypotension after 3-minute standing (systolic blood pressure drop \>=20 or diastolic blood pressure drop \>=10
Exclusion
- Drug-induced hypotension, if necessary, evaluate patient after discontinuing the causative drug for one month
- Heart failure or Chronic renal failure
- Severe supine hypertension (Systolic Blood Pressure \>180 or Diastolic Blood Pressure\>110mmHg)
- Pregnant women, breast-feeding
- Unable to perform questionnaire
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03350659
Start Date
January 1 2018
End Date
March 15 2019
Last Update
April 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 03080